The Market and Future Potential for Molecular Point of Care (mPOC), 2023
9 Feb 2023
This report is an essential tool for understanding the size and growth opportunity in molecular POC. Molecular point of care (mPOC) has gone from novel trend to significant contributor to the market. The instruments sold by Abbott, BioMérieux, Cepheid and increasingly, a host of other companies, are a significant contributor to the IVD POC market. Knowing these markets is essential to knowing the opportunity in point of care testing and microbiology IVD.
Since 2013, Kalorama has been producing a dedicated report on systems and consumables. The Market and Future Potential for Molecular Point of Care (POC), 2023 is Kalorama’s latest. The report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.
Since 2013, Kalorama has been producing a dedicated report on systems and consumables. The Market and Future Potential for Molecular Point of Care (POC), 2023 is Kalorama’s latest. The report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.
Table of Contents
-
Chapter 1: Executive Summary
- Where is Molecular Point of Care in 2023?
-
Molecular Point of Care Market Analysis
- Market Observations
- “Near-Patient” Molecular Systems Market
- Current Trends
- Molecular Point-of-Care Diagnostics Defined
- Usage of Molecular Point of Care
- Leading mPOC Platforms
- Trends
- Scope and Methodology
-
Chapter 2: Molecular Point-of-Care Market Development and Trends
-
COVID-19 and Molecular POC
- CDC Initial Response, Long Term Situation
- COVID-19’s Unique Challenge
- BARDA Directs Funding to mPOC
- Recent Regulatory Developments
- Consortia, Funding, Prizes
- Deals
- Advantages and Disadvantages of Molecular Point of Care
- Justification: The Sensitivity/Specificity Argument
-
New Systems and Menu Expansion
- Mesa Biotech Strep A Approval
- Combination Tests Enter Market: SARS-CoV-2, Flu A, Flu B, and RSV
- STI Continues to Be a Growth Area
-
Deals, Investment in mPOC Systems
- Thermo Acquires Mesa Biotech
- EU Researchers Awarded €3M to Develop POC Molecular Tests
- Scope Fluidics AST System Sees Investment
- China as a POC Market
- Common Tests and Analytes in POC Diagnostics
-
Component Technologies of Molecular Point-of-Care Diagnostics
- Microfluidics
- qPCR
- Microarrays
- Isothermal Amplification
- Test Automation
- Primers and Probes
- Detection
- Next-Generation Sequencing
- Molecular Diagnostics
- Real-Time PCR (qPCR)
- Isothermal Amplification Methods
- Line Probe Assays
- Next-Generation Sequencing
-
Applications and Potential Applications for Molecular Point-of-Care
- Major Testing Applications for Molecular POC Diagnostics
- Influenza
- Reclassification of RIDTs
- Hospital-Acquired Infections (HAIs)
- Strep A
- Respiratory Syncytial Virus (RSV)
- Emerging Applications
- Zika
- Other Respiratory Infections
- Group B Streptococcus
- Human Papillomavirus
- Herpes Simplex Virus
- Vaginitis
- Tuberculosis
- Malaria
- Other Tropical and Neglected Diseases
- Cancer
- European Device Regulations Nearing
-
COVID-19 and Molecular POC
-
Chapter 3: Market Analysis
- Molecular Point of Care Market Analysis
-
“Near Patient Molecular” Market
- Market Share Near Patient
-
Chapter 4: Company Profiles
- Abbott Laboratories
- Aidian Oy
- Akonni Biosystems
- binx health, inc.
- Biocartis NV
- bioMérieux SA
-
Cepheid (Danaher)
- Molecular Healthcare-Acquired Infection (HAI) Testing
- Molecular Sexual Health and Women’s Health Testing
- Molecular Critical Infectious Disease Testing
- Molecular Oncology/Genetics Testing
- Credo Bioscience
- Cue Health
- Curetis NV (OpGen)
- DiaSorin S.p.A
- GenMark Diagnostics (Roche)
- Greiner Bio-One GmbH
- Lucira Health
- Meridian Bioscience, Inc.
- Mesa Biotech, Inc. (Thermo)
- QIAGEN NV
- QuantuMDx Group
- QuidelOrtho Corporation
- Roche
- Sekisui Diagnostics LLC
- T2 Biosystems